The 2018 edition of China's NAFLD treatment guidelines also showed that the increase of ALT, AST, and other indicators is a high-risk factor for NAFLD to further develop to NASH [28]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.